ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för quisinostat. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

35 träffar

Bibliografisk träff 2024-05-01

New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.

Meneceur S, De Vos CE, Petzsch P, Köhrer K, Niegisch G, Hoffmann MJ.

J Cell Mol Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/jcmm.18342

Bibliografisk träff 2024-01-24

The Roles and Regulatory Mechanisms of Tight Junction Protein Cingulin and Transcription Factor Forkhead Box Protein O1 in Human Lung Adenocarcinoma A549 Cells and Normal Lung Epithelial Cells.

Ishii D, Shindo Y, Arai W, Konno T, Kohno T, Honda K, Miyajima M, Watanabe A, Kojima T.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms25031411

Bibliografisk träff 2023-11-22

Quisinostat is a brain-penetrant radiosensitizer in glioblastoma.

Lo Cascio C, Margaryan T, Luna-Melendez E, McNamara JB, White CI, Knight W, Ganta S, Opachich Z, Cantoni C, Yoo W, Sanai N, Tovmasyan A, Mehta S.

JCI Insight · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1172/jci.insight.167081

Bibliografisk träff 2023-08-19

Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma.

Noll A, Myers C, Biery MC, Meechan M, Tahiri S, Rajendran A, Berens ME, Paine D, Byron S, Zhang J, Winter C, Pakiam F, Leary SES, Cole BL, Jackson ER, Dun MD, Foster JB, Evans MK, Pattwell SS, Olson JM, Vitanza NA.

Neoplasia · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.neo.2023.100921

Bibliografisk träff 2022-05-28

HDAC inhibitor quisinostat prevents estrogen deficiency-induced bone loss by suppressing bone resorption and promoting bone formation in mice.

Sun S, Xiu C, Chai L, Chen X, Zhang L, Liu Q, Chen J, Zhou H.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2022.175073

Bibliografisk träff 2022-05-24

Inhibition of HDAC and Signal Transduction Pathways Induces Tight Junctions and Promotes Differentiation in p63-Positive Salivary Duct Adenocarcinoma.

Nakano M, Ohwada K, Shindo Y, Konno T, Kohno T, Kikuchi S, Tsujiwaki M, Ishii D, Nishida S, Kakuki T, Obata K, Miyata R, Kurose M, Kondoh A, Takano K, Kojima T.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers14112584

Bibliografisk träff 2022-02-17

Drug Repurposing of Quisinostat to Discover Novel <i>Plasmodium falciparum</i> HDAC1 Inhibitors with Enhanced Triple-Stage Antimalarial Activity and Improved Safety.

Wang M, Tang T, Li R, Huang Z, Ling D, Zheng L, Ding Y, Liu T, Xu W, Zhu F, Min H, Boonhok R, Mao F, Zhu J, Li X, Jiang L, Li J.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c01993

Bibliografisk träff 2021-12-01

Species-selective targeting of pathogens revealed by the atypical structure and active site of Trypanosoma cruzi histone deacetylase DAC2.

Marek M, Ramos-Morales E, Picchi-Constante GFA, Bayer T, Norström C, Herp D, Sales-Junior PA, Guerra-Slompo EP, Hausmann K, Chakrabarti A, Shaik TB, Merz A, Troesch E, Schmidtkunz K, Goldenberg S, Pierce RJ, Mourão MM, Jung M, Schultz J, Sippl W, Zanchin NIT, Romier C.

Cell Rep · research support, non-u.s. gov't; journal article · DOI 10.1016/j.celrep.2021.110129

Bibliografisk träff 2021-11-02

Nano-Assembly of Quisinostat and Biodegradable Macromolecular Carrier Results in Supramolecular Complexes with Slow-Release Capabilities.

Chowdhury A, Marin A, Weber DJ, Andrianov AK.

Pharmaceutics · research-article; journal article · DOI 10.3390/pharmaceutics13111834

Bibliografisk träff 2021-05-15

Inhibition of osteoclastogenesis by histone deacetylase inhibitor Quisinostat protects mice against titanium particle-induced bone loss.

Zhang L, Zhang L, You H, Sun S, Liao Z, Zhao G, Chen J.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2021.174176

Bibliografisk träff 2021-05-11

Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.

Shindo Y, Arai W, Konno T, Kohno T, Kodera Y, Chiba H, Miyajima M, Sakuma Y, Watanabe A, Kojima T.

Histochem Cell Biol · journal article · DOI 10.1007/s00418-021-01966-1

Bibliografisk träff 2021-05-01

Quisinostat mediated autophagy is associated with differentiation in neuroblastoma SK-N-SH cells.

Kommalapati VK, Kumar D, Tangutur AD.

Mol Biol Rep · journal article · DOI 10.1007/s11033-021-06481-z

Bibliografisk träff 2021-04-28

Comment on "Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma".

Lin J.

Invest New Drugs · letter; comment · DOI 10.1007/s10637-021-01124-3

Bibliografisk träff 2021-03-10

Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening.

Grad I, Hanes R, Ayuda-Durán P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0248140

Bibliografisk träff 2020-12-05

Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis.

Wang X, Liu K, Gong H, Li D, Chu W, Zhao D, Wang X, Xu D.

Toxicol Appl Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.taap.2020.115363

Bibliografisk träff 2020-04-14

Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis.

Morales Torres C, Wu MY, Hobor S, Wainwright EN, Martin MJ, Patel H, Grey W, Grönroos E, Howell S, Carvalho J, Snijders AP, Bustin M, Bonnet D, Smith PD, Swanton C, Howell M, Scaffidi P.

Nat Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41467-020-15615-z

Bibliografisk träff 2020-03-07

Inhibition of JNJ-26481585-mediated autophagy induces apoptosis via ROS activation and mitochondrial membrane potential disruption in neuroblastoma cells.

Kommalapati VK, Kumar D, Tangutur AD.

Mol Cell Biochem · journal article · DOI 10.1007/s11010-020-03708-8

Bibliografisk träff 2019-05-11

Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis.

Steelant B, Wawrzyniak P, Martens K, Jonckheere AC, Pugin B, Schrijvers R, Bullens DM, Vanoirbeek JA, Krawczyk K, Dreher A, Akdis CA, Hellings PW.

J Allergy Clin Immunol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jaci.2019.04.027

Bibliografisk träff 2018-11-08

Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.

Marek M, Shaik TB, Heimburg T, Chakrabarti A, Lancelot J, Ramos-Morales E, Da Veiga C, Kalinin D, Melesina J, Robaa D, Schmidtkunz K, Suzuki T, Holl R, Ennifar E, Pierce RJ, Jung M, Sippl W, Romier C.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.8b01087

Bibliografisk träff 2018-10-20

The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction.

He B, Dai L, Zhang X, Chen D, Wu J, Feng X, Zhang Y, Xie H, Zhou L, Wu J, Zheng S.

Int J Biol Sci · research support, non-u.s. gov't; research-article; journal article · DOI 10.7150/ijbs.27661

Bibliografisk träff 2018-07-18

Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.

Méhul B, Perrin A, Grisendi K, Galindo AN, Dayon L, Ménigot C, Rival Y, Voegel JJ.

J Proteomics · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jprot.2018.07.003

Bibliografisk träff 2018-04-27

Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.

Enßle JC, Boedicker C, Wanior M, Vogler M, Knapp S, Fulda S.

Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2018.04.032

Bibliografisk träff 2017-06-15

Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.

Haydn T, Metzger E, Schuele R, Fulda S.

Cell Death Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/cddis.2017.239

Bibliografisk träff 2015-11-30

Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma.

Heinicke U, Kupka J, Fichter I, Fulda S.

Oncogene · research support, non-u.s. gov't; journal article · DOI 10.1038/onc.2015.440

Bibliografisk träff 2015-11-01

JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis.

Heinicke U, Kupka J, Fulda S.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.6097

Bibliografisk träff 2014-08-02

Effect of histone deacetylase inhibitor JNJ-26481585 in pain.

Capasso KE, Manners MT, Quershi RA, Tian Y, Gao R, Hu H, Barrett JE, Sacan A, Ajit SK.

J Mol Neurosci · research support, non-u.s. gov't; journal article · DOI 10.1007/s12031-014-0391-7

Bibliografisk träff 2013-09-04

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.

Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R.

Pediatr Blood Cancer · research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/pbc.24724

Bibliografisk träff 2013-06-05

A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.

Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, Fourneau N, Hellemans P, Elsayed Y, McClue S, Smit JW, Forslund A, Phelps C, Camm J, Evans TR, de Bono JS, Banerji U.

Clin Cancer Res · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1158/1078-0432.ccr-13-0312

Bibliografisk träff 2012-10-17

Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585.

Schreml J, Riessland M, Paterno M, Garbes L, Roßbach K, Ackermann B, Krämer J, Somers E, Parson SH, Heller R, Berkessel A, Sterner-Kock A, Wirth B.

Eur J Hum Genet · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/ejhg.2012.222

Bibliografisk träff 2010-03-13

Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.

Stühmer T, Arts J, Chatterjee M, Borawski J, Wolff A, King P, Einsele H, Leo E, Bargou RC.

Br J Haematol · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1365-2141.2010.08126.x